ASAP Research Round-Up | Q1 2025
In this first edition of the ASAP Research Round-Up, ASAP shares advancements in Q1 2025 across the ASAP portfolio that fill critical knowledge gaps, promote rapid dissemination of scientific insights, expand resource accessibility, and support the next generation of Parkinson’s researchers.
2024: A Year in Review
ASAP is excited to share how we pushed the Parkinson’s disease research field forward. Together, our supported programs worked to funnel new ideas into Parkinson’s disease R&D, facilitate the rapid exchange of ideas, ensure researchers can build upon ASAP-funded work, and establish a diverse pipeline for the next generation of researchers.
The Components of GP2’s Eighth Data Release
In September 2024, GP2 announced the eighth data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 5,481 additional whole genome sequences and 10,454 clinical exome sequences. Additional genotyping will be provided in the following release.
The Components of GP2’s Seventh Data Release
In April 2024, GP2 announced the seventh data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes >9,000 additional genotyped participants.
The Components of GP2’s Sixth Data Release
In December 2023, GP2 announced the sixth data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes >20,000 additional participants, adding to the previous releases from the Complex and Monogenic Networks.
2023: A Year in Review
ASAP reflects on the results our initiative, network, and supported programs have had on providing new insights into Parkinson’s disease in 2023. Together, we have uncovered novel discoveries and made progress toward our vision of advancing collaborative, transparent research processes, and environments that deliver faster and better outcomes in PD research.
Risk Factor for Parkinson’s Discovered in Genes From People of African Descent
Read NPR's coverage of GP2's historic GBA1 finding. This article by Jon Hamilton includes interviews with ASAP's Managing Director, Dr. Ekemini A. U. Riley, and lead GP2 study researchers, Andy Singleton and Sara Bandres-Ciga.
Gene Variant Found Linking People of African Descent to Higher Parkinson’s Risk
Dr. Ekemini A. U. Riley, managing director of ASAP, joins PBS NewsHour to discuss findings from the GBA1 discovery and the power of collaborative, open science to unlock discoveries for populations traditionally underrepresented in research.
UNILAG Researchers Unravel Novel Parkinson’s Genetic Risk Factor in Africans
The Guardian Nigeria reports on GP2 and its collaboration with the University of Lagos (UNILAG) to uncover a genetic variant that increases the risk of PD in Africans and African admixed populations.
The Components of GP2’s Fifth Data Release
In May 2023, GP2 announced the fifth data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 7,462 additional new complex disease participants and 487 new monogenic disease participants, adding to the previous releases from the Complex and Monogenic Networks.
The Components of GP2’s Fourth Data Release
In February 2023, GP2 announced the fourth data release on the Terra platform in collaboration with AMP® PD. This release includes 2,583 additional new complex disease participants, adding to the previous releases from the Complex and Monogenic Networks.
GP2 Cohort Dashboard Now Includes New Ancestry Categories
The updated GP2 Cohort dashboard now includes additional ancestry information across cohort samples that have already been processed and shared with the AMP® PD platform.
2022: A Year in Review
ASAP reflects on the progress made in 2022 toward our vision of advancing collaborative, transparent research processes and environments that deliver faster and better outcomes in Parkinson’s disease research.
The Components of GP2’s Third Data Release
In October 2022, GP2 announced the third data release on the Terra platform in collaboration with AMP® PD. This release includes 6,330 additional new complex disease participants, adding to the previous releases from the Complex and Monogenic Networks.
GP2 Trainees Offer Perspective on Annual Investigators Meeting
GP2's trainee network consists of nearly 150 members worldwide. Some of these trainees recently attended the inaugural Annual Investigators Meeting in Madrid, Spain. Take a look at their impressions of the meeting and GP2's ambitious work.
The Components of GP2’s Second Data Release
In April 2022, GP2 announced the second data release on the Terra platform in collaboration with AMP® PD. This release contains data from both complex and monogenic GP2 networks. The complex disease data now consists of a total of 8,644 genotyped participants (5,249 PD, 3,395 non-PD).
GP2 Celebrates the International Day of Women and Girls in Science
Women scientists have historically gone unrecognized for their fundamental contributions. Today and every day, GP2 recognizes and works to empower women to lead, create, and innovate in the field of PD genetics around the world.
The Components of GP2’s First Data Release
In December 2021, GP2 announced its first GP2 data release on the AMP® PD platform. The data available consists of 4,908 participants (3,434 PD, 1,474 non-PD) from the CORIELL, Baylor College of Medicine (BCM), and BCM-University of Maryland (UMD) cohorts.
GP2 Awards New Trainees
As the demand for Parkinson's disease genetics specialists continues to grow, GP2 is committed to providing opportunities and training to researchers around the world. With GP2's support, the work and discoveries of our next generation of researchers will accelerate the path to a cure for PD.
Promoting Diversity, Equity and Inclusion in Parkinson’s Research and Care
Medical Xpress reports on The Michael J. Fox Foundation for Parkinson's Research’s work to diversify PD research.
